Apr 01, 2020
New Telehealth Service Helps Reduce Relapse Risk for Those in Recovery; Hiring Increased by 50% to Meet Demand
Mar 09, 2020
DrFirst and GoHipo Partner to Use Telehealth to Fight High Relapse Rates After Substance Abuse Treatment by Addressing Major Gaps in Post-Inpatient Rehabilitation
Feb 27, 2020
Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020
Nov 07, 2019
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population
Sep 13, 2019
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse
Mar 28, 2019
Amygdala Neurosciences Announces Dosing the First Patients in the $12.4 Million NIH HEAL Initiative Funded SEARCH Program of Clinical Studies with ANS-6637
Feb 26, 2019
The Issue of Relapse and Addiction Tackled by Recovery Centers of America in New Treatment Program at Devon, PA Campus
Jan 31, 2019
CHESS Health, Australian Justice Center Partner to Provide eRecovery Technology to Substance Use Disorder Clients
Jan 17, 2019
American Addiction Centers Releases Five Tips to Beat the Winter Blues & Stay Sober
Dec 13, 2018
Drug and Alcohol Relapse Rates Spike 150% during the Holidays
Nov 16, 2018
American Addiction Centers Releases 10 Tips to Stay Sober During the Holidays
Sep 19, 2018
Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies
Sep 12, 2018
Amygdala Neurosciences and NIAAA will Conduct a Phase 2 Clinical study of ANS-6637 for the Treatment of Alcohol Use Disorder
Aug 28, 2018
Brain Research Foundation (BRF) awards two grants to help identify new treatments to reduce opioid relapse
Oct 27, 2017
Patient Survey Studies Find Multiple Sclerosis Relapse is Underreported; Approximately Half of Patients Do Not Always Engage with Healthcare Practitioners During Relapse
Oct 26, 2017
Mallinckrodt plc Presents Multiple Sclerosis (MS) Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)
Aug 01, 2017
Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder